Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8003632rdf:typepubmed:Citationlld:pubmed
pubmed-article:8003632lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C0021760lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C0016030lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C0021755lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C0012472lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C0069535lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:8003632lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:8003632pubmed:issue1lld:pubmed
pubmed-article:8003632pubmed:dateCreated1994-7-15lld:pubmed
pubmed-article:8003632pubmed:abstractTextThe role of Oncostatin M (OM), a monocyte/macrophage and T-cell product, in regulating IL-6 expression in fibroblasts of lung or synovial origin was examined in vitro. Although by itself OM had a minimal effect on enhancing IL-6 production by fibroblasts, in combination with IL-1 alpha or PGE2, OM addition resulted in a dose-dependent synergistic enhancement of IL-6 production. This synergistic effect with either IL-1 alpha (5 ng/ml) or PGE2 (10(-7) M) was clearly evident at concentrations of OM of 10, 20 or 50 ng/ml. Levels of IL-6 resulting from OM and IL-1 alpha stimulation could be reduced by indomethacin (10(-6) M) and restored again by also adding PGE2. Northern blots probed for IL-6 mRNA showed cooperative enhancement of steady state levels at 18 hours of stimulation by OM and IL-1 alpha, or OM and PGE2. Probing for mRNA of the metalloproteinase inhibitor TIMP-1 showed that stimulation by OM, IL-1 alpha or PGE2 enhanced TIMP-1 levels. However, OM (alone) or PGE2 or both combined did not elevate the metalloproteinase stromelysin-1 mRNA signals. Analysis utilizing a rat IL-6 promoter-luciferase reporter gene construct showed that OM stimulation resulted in activation of transcription that synergistically enhanced IL-1-induced levels of reporter gene expression. These results show that although OM has minor effects on IL-6 production alone, the combination of OM and other mediators result in markedly enhanced IL-6 production by fibroblasts in vitro.lld:pubmed
pubmed-article:8003632pubmed:languageenglld:pubmed
pubmed-article:8003632pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:citationSubsetIMlld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8003632pubmed:statusMEDLINElld:pubmed
pubmed-article:8003632pubmed:monthJanlld:pubmed
pubmed-article:8003632pubmed:issn1043-4666lld:pubmed
pubmed-article:8003632pubmed:authorpubmed-author:RichardsC DCDlld:pubmed
pubmed-article:8003632pubmed:authorpubmed-author:AgroAAlld:pubmed
pubmed-article:8003632pubmed:issnTypePrintlld:pubmed
pubmed-article:8003632pubmed:volume6lld:pubmed
pubmed-article:8003632pubmed:ownerNLMlld:pubmed
pubmed-article:8003632pubmed:authorsCompleteYlld:pubmed
pubmed-article:8003632pubmed:pagination40-7lld:pubmed
pubmed-article:8003632pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:meshHeadingpubmed-meshheading:8003632-...lld:pubmed
pubmed-article:8003632pubmed:year1994lld:pubmed
pubmed-article:8003632pubmed:articleTitleInteraction between oncostatin M, interleukin 1 and prostaglandin E2 in induction of IL-6 expression in human fibroblasts.lld:pubmed
pubmed-article:8003632pubmed:affiliationDepartment of Pathology, McMaster University, Hamilton, Ontario, Canada.lld:pubmed
pubmed-article:8003632pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8003632pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8003632lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8003632lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8003632lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8003632lld:pubmed